MTFL457 could be an alternative cerebroprotective agent used as an adjunct to reperfusion or, additionally, as an enhancer of therapies for neurological and psychiatric diseases based on the use of BDNF or small size analogues [24], which are challenged by TrkB-FL downregulation and GA damage induced by excitotoxicity. This evidence concerns the gene NTRK2 and psychiatric disorder.